Economic Comparison of Rivaroxaban with Enoxaparin in the UK and Sweden

u Venous thromboembolism (VTE) is the composite of deep vein thrombosis (DVT) and pulmonary embolism (PE) u The risk of VTE is increased after total hip replacement (THR) and total knee replacement (TKR) surgery. 1 With more than 400,000 such procedures performed annually in the European Union the potential public health risk is sizeable 2 u Rivaroxaban is an oral, direct Factor Xa inhibitor that received marketing approval in 2008 in the European Union and several other countries for the prevention of VTE after elective THR and TKR surgery